268 related articles for article (PubMed ID: 25823738)
21. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
[TBL] [Abstract][Full Text] [Related]
22. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy.
McClanahan F; Hielscher T; Rieger M; Hensel M; Neben K; Hillengass J; Herfarth K; Ho AD; Witzens-Harig M
Eur J Haematol; 2010 Jul; 85(1):11-9. PubMed ID: 20331739
[TBL] [Abstract][Full Text] [Related]
24. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
[TBL] [Abstract][Full Text] [Related]
26. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
van Oers MH; Tönnissen E; Van Glabbeke M; Giurgea L; Jansen JH; Klasa R; Marcus RE; Wolf M; Kimby E; Vranovsky A; Holte H; Hagenbeek A; van der Reijden BA
J Clin Oncol; 2010 May; 28(13):2246-52. PubMed ID: 20368567
[TBL] [Abstract][Full Text] [Related]
27. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
28. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.
Harjunpää A; Taskinen M; Nykter M; Karjalainen-Lindsberg ML; Nyman H; Monni O; Hemmer S; Yli-Harja O; Hautaniemi S; Meri S; Leppä S
Br J Haematol; 2006 Oct; 135(1):33-42. PubMed ID: 16925574
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.
Drake MT; Maurer MJ; Link BK; Habermann TM; Ansell SM; Micallef IN; Kelly JL; Macon WR; Nowakowski GS; Inwards DJ; Johnston PB; Singh RJ; Allmer C; Slager SL; Weiner GJ; Witzig TE; Cerhan JR
J Clin Oncol; 2010 Sep; 28(27):4191-8. PubMed ID: 20713849
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
31. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
[TBL] [Abstract][Full Text] [Related]
32. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
[TBL] [Abstract][Full Text] [Related]
33. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
Carlotti E; Palumbo GA; Oldani E; Tibullo D; Salmoiraghi S; Rossi A; Golay J; Pulsoni A; Foà R; Rambaldi A
Haematologica; 2007 Aug; 92(8):1127-30. PubMed ID: 17650444
[TBL] [Abstract][Full Text] [Related]
34. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
[No Abstract] [Full Text] [Related]
35. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
[TBL] [Abstract][Full Text] [Related]
36. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.
Taskinen M; Karjalainen-Lindsberg ML; Leppä S
Blood; 2008 May; 111(9):4664-7. PubMed ID: 18309035
[TBL] [Abstract][Full Text] [Related]
37. Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.
Ternant D; Hénin E; Cartron G; Tod M; Paintaud G; Girard P
Br J Clin Pharmacol; 2009 Oct; 68(4):561-73. PubMed ID: 19843059
[TBL] [Abstract][Full Text] [Related]
38. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
Ladetto M; De Marco F; Benedetti F; Vitolo U; Patti C; Rambaldi A; Pulsoni A; Musso M; Liberati AM; Olivieri A; Gallamini A; Pogliani E; Rota Scalabrini D; Callea V; Di Raimondo F; Pavone V; Tucci A; Cortelazzo S; Levis A; Boccadoro M; Majolino I; Pileri A; Gianni AM; Passera R; Corradini P; Tarella C; ;
Blood; 2008 Apr; 111(8):4004-13. PubMed ID: 18239086
[TBL] [Abstract][Full Text] [Related]
39. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
40. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
